Sunday, February 22 2009
FDA Public Health Advisory Concerning Raptiva [Feb. 19. 2009]
Raptiva (efalizumab) Warning urged by FDA due to reports of three confirmed cases and one possible case of progressive multifocal leukoencephalopathy (PML) in patients. The patients of Raptiva were 47 to 73 years of age who were using Raptiva for the treatment of psoriasis. Two of the Raptiva patients with confirmed PML and one patient with possible PML died. All four patients were treated with Raptiva continuously for more than three years. None of the patients were receiving other treatments that suppress the immune system while taking Raptiva.
Progressive multifocal leukoencephalopathy (PML) is a rare, serious, progressive neurologic disease caused by a virus that affects the central nervous system. When PML occurs, it is usually in people whose immune systems have been severely weakened and often results in an irreversible decline in neurologic function and death. Read more about Raptiva Side Effects and other information about the Psoriasis drug Raptiva causing serious brain infections, sepsis and meningitis at Raptiva brain infections and meningitis.